Showing results (21-30 of 139) with videos related to

Sort By:
Pageof 14
Open Forum Infectious Diseases|October 23, 2024
Ideal Time to Conduct a Pharmacokinetic Investigation After Delivery to Fully Capture the Effect of Pregnancy on Drug ExposureMattia Berton, Felix Stader, Sara Bettonte, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2022
Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling StudySara Bettonte, Mattia Berton, Felix Stader, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 3, 2024
Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling StudySara Bettonte, Mattia Berton, Felix Stader, et al.
British Journal of Clinical Pharmacology|July 31, 2023
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimenSara Bettonte, Mattia Berton, Felix Stader, et al.
Open Forum Infectious Diseases|July 27, 2023
Impact of Obesity on the Drug-Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong InducersMattia Berton, Sara Bettonte, Felix Stader, et al.
Clinical Pharmacokinetics|December 26, 2022
Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese IndividualsMattia Berton, Sara Bettonte, Felix Stader, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 6, 2023
Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 SubstratesSara Bettonte, Mattia Berton, Felix Stader, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 16, 2015
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapiesDarren Michael Moss, Catia Marzolini, Rajith K R Rajoli, et al.
The Journal of Antimicrobial Chemotherapy|November 18, 2021
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIVTom G Jacobs, Catia Marzolini, David J Back, et al.
Molecular Pharmaceutics|April 27, 2013
The brain entry of HIV-1 protease inhibitors is facilitated when used in combinationCatia Marzolini, Rita Mueller, Xiaochun Li-Blatter, et al.
Pageof 14